Wntrx Pharmaceuticals Inc.

David Zhu

Robert B Perni

Yvonne Angell

Methods for treating cancer with a stabilized BCL9 peptide are encompassed, wherein the stabilized peptide comprises a portion of the HD2 domain of the BCL9 protein containing a hydrocarbon crosslinker generated using α,α-disubstituted amino acids.

Stabilized BCL9 peptides for treatment of aberrant Wnt signaling

Disclosed here are polypeptides derived from the HD2 domain of human B-cell CLL/lymphoma 9 (BCL9) protein and variants thereof, as well as their use in the diagnosis, prevention, and/or treatment of a disease or disorder. Also disclosed are methods of generating such polypeptides and variants thereof.

BCL9 peptides and variants thereof

Methods for treating cancer with a stabilized BCL9 peptide are encompassed, wherein the stabilized peptide comprises a portion of the HD2 domain of the BCL9 protein containing a hydrocarbon crosslinker generated using &#x3b1;, &#x3b1;-disubstituted amino acids.

Growing community of inventors

Newton, MA, United States of America

David Zhu